Sputum bacterial microbiota signature as a surrogate for predicting disease progression of nontuberculous mycobacterial lung disease
- PMID: 38740280
- DOI: 10.1016/j.ijid.2024.107085
Sputum bacterial microbiota signature as a surrogate for predicting disease progression of nontuberculous mycobacterial lung disease
Abstract
Objectives: Predicting progression of nontuberculous mycobacterial lung disease (NTM-LD) remains challenging. This study evaluated whether sputum bacterial microbiome diversity can be the biomarker and provide novel insights into related phenotypes and treatment timing.
Methods: We analyzed 126 sputum microbiomes of 126 patients with newly diagnosed NTM-LD due to Mycobacterium avium complex, M. abscessus complex, and M. kansasii between May 2020 and December 2021. Patients were followed for 2 years to determine their disease progression status. We identified consistently representative genera that differentiated the progressor and nonprogressor by using six methodologies. These genera were used to construct a prediction model using random forest with 5-fold cross validation.
Results: Disease progression occurred in 49 (38.6%) patients. Compared with nonprogressors, α-diversity was lower in the progressors. Significant compositional differences existed in the β-diversity between groups (p=0.001). The prediction model for NTM-LD progression constructed using seven genera (Burkholderia, Pseudomonas, Sphingomonas, Candidatus Saccharibacteria, Phocaeicola, Pelomonas, and Phascolarctobacterium) with significantly differential abundance achieved an area under curve of 0.871.
Conclusions: Identification of the composition of sputum bacterial microbiome facilitates prediction of the course of NTM-LD, and maybe used to develop precision treatment involving modulating the respiratory microbiome composition to ameliorate NTM-LD.
Keywords: lung disease; nontuberculous mycobacterium; prediction; progression; sputum microbiota.
Copyright © 2024. Published by Elsevier Ltd.
Conflict of interest statement
Conflict of interest All authors have no conflicts of interest relevant to this study to declare.
Similar articles
-
Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01105-18. doi: 10.1128/AAC.01105-18. Print 2018 Oct. Antimicrob Agents Chemother. 2018. PMID: 30104265 Free PMC article.
-
Microbiome Diversity in Sputum of Nontuberculous Mycobacteria Infected Women with a History of Breast Cancer.Cell Physiol Biochem. 2019;52(2):263-279. doi: 10.33594/000000020. Epub 2019 Feb 28. Cell Physiol Biochem. 2019. PMID: 30816674
-
[Analysis of time for diagnosis of nontuberculous mycobacterial lung disease and its associated factors in a tuberculosis-designated hospital in Shanghai].Zhonghua Jie He He Hu Xi Za Zhi. 2023 Apr 12;46(4):380-387. doi: 10.3760/cma.j.cn112147-20230111-00018. Zhonghua Jie He He Hu Xi Za Zhi. 2023. PMID: 36990702 Chinese.
-
Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease.J Korean Med Sci. 2016 May;31(5):649-59. doi: 10.3346/jkms.2016.31.5.649. Epub 2016 Mar 22. J Korean Med Sci. 2016. PMID: 27134484 Free PMC article. Review.
-
The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults.Drug Des Devel Ther. 2020 Jun 10;14:2287-2294. doi: 10.2147/DDDT.S146111. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32606598 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Research Materials